EQUINOX NEPREMICNINE d.d Balance Sheet Health
Financial Health criteria checks 4/6
EQUINOX NEPREMICNINE d.d has a total shareholder equity of €37.6M and total debt of €8.5M, which brings its debt-to-equity ratio to 22.7%. Its total assets and total liabilities are €51.2M and €13.6M respectively. EQUINOX NEPREMICNINE d.d's EBIT is €565.1K making its interest coverage ratio -0.5. It has cash and short-term investments of €65.2K.
Key information
22.7%
Debt to equity ratio
€8.55m
Debt
| Interest coverage ratio | -0.5x |
| Cash | €65.20k |
| Equity | €37.60m |
| Total liabilities | €13.56m |
| Total assets | €51.16m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: EQNX's short term assets (€1.5M) exceed its short term liabilities (€1.3M).
Long Term Liabilities: EQNX's short term assets (€1.5M) do not cover its long term liabilities (€12.3M).
Debt to Equity History and Analysis
Debt Level: EQNX's net debt to equity ratio (22.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if EQNX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: EQNX's debt is well covered by operating cash flow (69.9%).
Interest Coverage: EQNX earns more interest than it pays, so coverage of interest payments is not a concern.